Press release
Non Muscle Invasive Bladder Cancer Pipeline 2024: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Aura Biosciences, Protara Therapeutics, Vaxiion Therapeutics
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Non Muscle Invasive Bladder Cancer pipeline constitutes 20+ key companies continuously working towards developing 25+ Non Muscle Invasive Bladder Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight."Non Muscle Invasive Bladder Cancer Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Non Muscle Invasive Bladder Cancer Market.
The Pipeline report for Non-Muscle Invasive Bladder Cancer provides a thorough evaluation of commercial and clinical aspects of pipeline products, spanning from pre-clinical development to market availability. It includes an extensive overview of each drug, detailing its mechanism of action, clinical studies, potential NDA approvals, and various product development activities. These encompass technology, collaborations, mergers, acquisitions, funding, designations, and other pertinent details related to the product's development.
Some of the key takeaways from the Non Muscle Invasive Bladder Cancer Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Non Muscle Invasive Bladder Cancer treatment therapies with a considerable amount of success over the years.
*
Non Muscle Invasive Bladder Cancer companies working in the treatment market are Tollys, Aura Biosciences, Protara Therapeutics, Vaxiion Therapeutics, Incyte Corporation, Janssen Pharmaceuticals, Theralase Technologies, Pfizer, BristolMyers Squibb, Asieris Pharmaceuticals, and others, are developing therapies for the Non Muscle Invasive Bladder Cancer treatment
*
Emerging Non Muscle Invasive Bladder Cancer therapies in the different phases of clinical trials are- TL-532, AU-011, TARA-002, VAX 014, Pemigatinib, Erdafitinib, TLD 1433, PF-06801591, Nivolumab, APL-1202, and others are expected to have a significant impact on the Non Muscle Invasive Bladder Cancer market in the coming years.
*
In October 2024, Aura Biosciences, Inc. (NASDAQ: AURA) announced encouraging early results from its ongoing Phase 1 clinical trial of bel-sar (AU-011) in patients with non-muscle invasive bladder cancer (NMIBC). The trial has enrolled 13 patients to date, with primary objectives focused on assessing the safety and feasibility of bel-sar administered locally, both as a standalone treatment (n=5) and with light activation (n=8). Secondary objectives include evaluating biological activity and immune-mediated changes within the tumor microenvironment (TME). Among the participants, 10 had low-grade disease, reflecting the approximately 70% prevalence of low-grade NMIBC in this patient population, while 3 had high-grade disease. In the group treated with bel-sar and light activation (n=8), 4 of 5 patients with low-grade disease achieved a clinical complete response, with no tumor cells detected upon histopathological evaluation. Additionally, 2 of 3 patients with high-grade disease showed visible tumor shrinkage on cystoscopy.
*
In October 2024, UroGen Pharma has announced the administration of the first dose in the Phase III UTOPIA clinical trial of its investigational drug, UGN-103 (mitomycin), an intravesical solution designed to treat low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The trial plans to enroll 87 participants and will evaluate the efficacy and safety of this potential treatment.
Non Muscle Invasive Bladder Cancer Overview
Non-Muscle Invasive Bladder Cancer (NMIBC) is a type of bladder cancer that remains confined to the inner lining of the bladder and has not spread to the muscle layer. It is the most common form of bladder cancer, typically diagnosed through urine tests, cystoscopy, and biopsy. NMIBC can be classified into low-grade or high-grade categories, with low-grade being less aggressive. While treatable, NMIBC requires ongoing monitoring due to its potential to recur or progress to muscle-invasive bladder cancer. Treatment often includes procedures like transurethral resection of the bladder tumor (TURBT) and intravesical therapies.
Get a Free Sample PDF Report to know more about Non Muscle Invasive Bladder Cancer Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/non-muscle-invasive-bladder-cancer-pipeline-insight [https://www.delveinsight.com/report-store/non-muscle-invasive-bladder-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging Non Muscle Invasive Bladder Cancer Drugs Under Different Phases of Clinical Development Include:
*
TL-532: Tollys
*
AU-011: Aura Biosciences
*
TARA-002: Protara Therapeutics
*
VAX 014: Vaxiion Therapeutics
*
Pemigatinib: Incyte Corporation
*
Erdafitinib: Janssen Pharmaceuticals
*
TLD 1433: Theralase Technologies
*
PF-06801591: Pfizer
*
Nivolumab: BristolMyers Squibb
*
APL-1202: Asieris Pharmaceuticals
Non Muscle Invasive Bladder Cancer Route of Administration
Non Muscle Invasive Bladder Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
*
Oral
*
Parenteral
*
Intravenous
*
Subcutaneous
*
Topical
Non Muscle Invasive Bladder Cancer Molecule Type
Non Muscle Invasive Bladder Cancer Products have been categorized under various Molecule types, such as
*
Recombinant fusion proteins
*
Small molecule
*
Monoclonal antibody
*
Peptide
*
Polymer
*
Gene therapy
Non Muscle Invasive Bladder Cancer Pipeline Therapeutics Assessment
*
Non Muscle Invasive Bladder Cancer Assessment by Product Type
*
Non Muscle Invasive Bladder Cancer By Stage and Product Type
*
Non Muscle Invasive Bladder Cancer Assessment by Route of Administration
*
Non Muscle Invasive Bladder Cancer By Stage and Route of Administration
*
Non Muscle Invasive Bladder Cancer Assessment by Molecule Type
*
Non Muscle Invasive Bladder Cancer by Stage and Molecule Type
DelveInsight's Non Muscle Invasive Bladder Cancer Report covers around 25+ products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Further Non Muscle Invasive Bladder Cancer product details are provided in the report. Download the Non Muscle Invasive Bladder Cancer pipeline report to learn more about the emerging Non Muscle Invasive Bladder Cancer therapies [https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the Non Muscle Invasive Bladder Cancer Therapeutics Market include:
Key companies developing therapies for Non Muscle Invasive Bladder Cancer are - Tollys, Vaxiion Therapeutics, Incyte Corporation, Janssen Pharmaceuticals, Theralase Technologies, Pfizer, Bristol-Myers Squibb, Asieris Pharmaceuticals, UroGen Pharma, CG Oncology, Sesen Bio, Hamlet Pharma, AstraZeneca, Viralytics, ImmunityBio, Prokarium, Abraxis Bioscience, LIPAC Oncology, Rapamycin Holdings, Taizhou Hanzhong Biomedical, Spectrum Pharmaceuticals, FKD therapies, Altor Biosciences, Heat Biologics, EMD Sereno, QED Therapeutics, and others.
Non Muscle Invasive Bladder Cancer Pipeline Analysis:
The Non Muscle Invasive Bladder Cancer pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of Non Muscle Invasive Bladder Cancer with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non Muscle Invasive Bladder Cancer Treatment.
*
Non Muscle Invasive Bladder Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Non Muscle Invasive Bladder Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non Muscle Invasive Bladder Cancer market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Non Muscle Invasive Bladder Cancer drugs and therapies [https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Non Muscle Invasive Bladder Cancer Pipeline Market Drivers
*
Increase in the number of patients suffering from non-muscle invasive bladder cancer. Approximately 70-75%bladder cancers are non-muscle invasive bladder cancer (NMIBC), development of novel therapies and favorable government policies are some of the important factors that are fueling the Non Muscle Invasive Bladder Cancer Market.
Non Muscle Invasive Bladder Cancer Pipeline Market Barriers
*
However, identifying the patient population with specific mutations for targeted therapy regimens, lack of awareness about the advanced cancer therapies and other factors are creating obstacles in the Non Muscle Invasive Bladder Cancer Market growth.
Scope of Non Muscle Invasive Bladder Cancer Pipeline Drug Insight
*
Coverage: Global
*
Key Non Muscle Invasive Bladder Cancer Companies: Tollys, Aura Biosciences, Protara Therapeutics, Vaxiion Therapeutics, Incyte Corporation, Janssen Pharmaceuticals, Theralase Technologies, Pfizer, BristolMyers Squibb, Asieris Pharmaceuticals, and others
*
Key Non Muscle Invasive Bladder Cancer Therapies: TL-532, AU-011, TARA-002, VAX 014, Pemigatinib, Erdafitinib, TLD 1433, PF-06801591, Nivolumab, APL-1202, and others
*
Non Muscle Invasive Bladder Cancer Therapeutic Assessment: Non Muscle Invasive Bladder Cancer current marketed and Non Muscle Invasive Bladder Cancer emerging therapies
*
Non Muscle Invasive Bladder Cancer Market Dynamics: Non Muscle Invasive Bladder Cancer market drivers and Non Muscle Invasive Bladder Cancer market barriers
Request for Sample PDF Report for Non Muscle Invasive Bladder Cancer Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Non Muscle Invasive Bladder Cancer Report Introduction
2. Non Muscle Invasive Bladder Cancer Executive Summary
3. Non Muscle Invasive Bladder Cancer Overview
4. Non Muscle Invasive Bladder Cancer- Analytical Perspective In-depth Commercial Assessment
5. Non Muscle Invasive Bladder Cancer Pipeline Therapeutics
6. Non Muscle Invasive Bladder Cancer Late Stage Products (Phase II/III)
7. Non Muscle Invasive Bladder Cancer Mid Stage Products (Phase II)
8. Non Muscle Invasive Bladder Cancer Early Stage Products (Phase I)
9. Non Muscle Invasive Bladder Cancer Preclinical Stage Products
10. Non Muscle Invasive Bladder Cancer Therapeutics Assessment
11. Non Muscle Invasive Bladder Cancer Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Non Muscle Invasive Bladder Cancer Key Companies
14. Non Muscle Invasive Bladder Cancer Key Products
15. Non Muscle Invasive Bladder Cancer Unmet Needs
16 . Non Muscle Invasive Bladder Cancer Market Drivers and Barriers
17. Non Muscle Invasive Bladder Cancer Future Perspectives and Conclusion
18. Non Muscle Invasive Bladder Cancer Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=non-muscle-invasive-bladder-cancer-pipeline-2024-moa-roa-fdaapproved-drugs-and-clinical-trial-progress-assessment-by-delveinsight-aura-biosciences-protara-therapeutics-vaxiion-therapeutics]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Non Muscle Invasive Bladder Cancer Pipeline 2024: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Aura Biosciences, Protara Therapeutics, Vaxiion Therapeutics here
News-ID: 3830807 • Views: …
More Releases from ABNewswire

DanceUs.org Announces Major Platform Updates to Enhance User Experience and Disc …
DanceUs.org, a Los Angeles-based online dance portal, has announced significant updates to its website following extensive user testing. The platform has revamped its calendar and improved its event and class navigation to make it easier for users to discover local dance activities. The company invites the public to explore the new features to find dance classes and events nearby.
LOS ANGELES, CA - October 2, 2025 - DanceUs.org, the leading online…

CrownPoint Partners Brokers $11.5 Million Sale of Newly Constructed Tractor Supp …
NAPLES, Fla. - CrownPoint Partners is pleased to announce the sale of a newly constructed Tractor Supply Co. property in Naples, Florida, for $11.5 million.
Managing Partners Shannon Bona and Julius Swolsky of CrownPoint Partners represented the seller, a prominent developer based in the Southeast. The buyer, a private 1031 exchange investor from the Midwest, was represented by David Weinberg of Marcus & Millichap.
The asset is a brand-new prototype Tractor Supply…

Biliary Tract Cancer Market Expected to Gain Momentum Through 2034, According to …
The Key Biliary Tract Cancer Companies in the market include - Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Delcath Systems, TransThera Sciences (Nanjing), Basilea Pharmaceutica, Eisai, Zymeworks, BeiGene, Xencor, Inc., Bristol-Myers Squibb, Leap Therapeutics, Inc., Boehringer Ingelheim, ZielBio, Inc., GeneQuantum Healthcare (Suzhou) Co., Ltd., BioNTech SE, SOTIO Biotech, Carisma Therapeutics Inc, Rain Oncology Inc, Avacta Life Sciences Ltd, DualityBio Inc., and others.
DelveInsight's "Biliary Tract Cancer Market Insights, Epidemiology, and Market…

Le Perle introduces Poland's first dental concierge service, elevating patient e …
Le Perle in Poznan launches the first dental concierge service in Poland, offering travel coordination, luxury stays, cultural experiences, and remote treatment monitoring.
Poznan, Poland - Le Perle , the boutique dental atelier led by Dr. Anna Kusnierczak ( Stomatolog Dobra Rada ), has announced the launch of Poland's first dental concierge [https://www.leperle.pl] service, redefining the way patients experience comprehensive treatment. This innovation integrates dentistry with tailored lifestyle services, further strengthening…
More Releases for Muscle
Artificial Muscle Market Top Players - NAU, Bayer (Artificial Muscle, Inc.), Ste …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Artificial Muscle Market- (By Type (Electric Field Actuation, Pneumatic Actuation, Thermal Actuation), By Application (Industrial, Medical, Consumer, Automotive, Aerospace)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
According to the latest research by InsightAce Analytic, the Global Artificial Muscle Market is valued at US$ 2.23 Bn in 2022, and it is expected to reach US$…
Muscle Protein Powder Market Report Analysis, Research Studies |Vitalstrength, C …
[Nevada, October 2024] - Muscle Protein Powder has emerged as a cornerstone in the health and fitness industry, appealing to athletes, fitness enthusiasts, and even casual gym-goers seeking nutritional support for muscle recovery and growth. Derived from various sources, including whey, casein, soy, and plant-based proteins, these powders provide essential amino acids that aid in muscle synthesis and repair. As the world becomes increasingly health-conscious, the relevance of Muscle Protein…
Sports muscle tape bandage for athletes - Special muscle tape, muscle effect for …
Product Features
Image: https://ecdn6-nc.globalso.com/upload/p/950/image_other/2024-03/66029d7cc0d1029158.png
Pre-slitting muscle patch Knee PadPrevention of muscle strainNo need tocropBody molding without cutting
Image: https://ecdn6-nc.globalso.com/upload/p/950/image_other/2024-03/66029d8a65f1b43114.png
Medical lowsensitivity glue-acrylic glue Not easy to allergy no residueGood stickiness,soft and skin-friendly,comfortable and breathable
Image: https://ecdn6-nc.globalso.com/upload/p/950/image_other/2024-08/1-8.pngImage: https://ecdn6-nc.globalso.com/upload/p/950/image_other/2024-03/66029d83b5f6151157.png
Area-separated design for easy adhesion
Eliminate tedious cropping steps
Image: https://ecdn6-nc.globalso.com/upload/p/950/image_other/2024-03/66029d8f95d8390458.png
High elastic stretch without breaking
Full of elasticity, no sense of restraint in exercise, free stretching is not afraid of breaking product material
Image: https://ecdn6-nc.globalso.com/upload/p/950/image_other/2024-08/product-details-1440-751-px-7.jpg
TECHNICAL Parameters
Product size and weight
Weight
130g
Product attributes
protect part
knee
brand
Xinyouwei
Item number
Muscle tape-knee…
Artificial Muscle Market Gears Up for Growth Beyond Robotics: Unleashing the Pot …
Artificial Muscle Market worth $5.36 Bn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Artificial Muscle Market- (By Type (Electric Field Actuation, Pneumatic Actuation, Thermal Actuation), By Application (Industrial, Medical, Consumer, Automotive, Aerospace)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
According to the latest research by InsightAce Analytic, the Global Artificial Muscle Market…
Muscle Wave Pro Review 2023;(Amazing facts!( Is This Muscle Toner Worth It?
Muscle Wave Pro, also known as neuromuscular electrical stimulation or electromyostimulation, is a device that uses electrical impulses to stimulate muscle contractions. It is designed to mimic the natural electrical signals sent by the brain to muscles, causing them to contract and relax.
The basic principle behind Muscle Wave Pro is that electrical stimulation can activate motor nerves, which in turn activate muscles. The device consists of electrodes that are placed…
Artificial Muscle Market Research Report
Artificial muscles, which are also referred to as muscle-like actuators, are devices or materials that copy the functions of human muscle and can expand, contract, vary their stiffness, or rotate due to an external force (current, voltage, temperature, or pressure). There are three basic responses to actuation, expansion, contraction, and rotation. These can then be combined by a single device and used to create further different types of motion.
There…